KNSA

Paolini John F.

Known title: CHIEF MEDICAL OFFICERCIK: 0001741533

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 8, 2026

Kiniksa Reports Strong Growth and Accelerating Earnings. Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.

Transaction History

KNSA▲ Buy—
KNSA▲ Buy—
KNSA▲ Buy—
KNSA▼ Sell$319K
KNSA▲ Buy—
KNSA▲ Buy$605K
KNSA▼ Sell$2.0M
KNSA▼ Sell$1.1M
KNSA▲ Buy—
KNSA▼ Sell$59K
KNSA▲ Buy—
KNSA▼ Sell$136K
KNSA▲ Buy$414K
KNSA▼ Sell$533K
KNSA▼ Sell$997K
KNSA▼ Sell$262K
KNSA▲ Buy$139K
KNSA▲ Buy$406K
KNSA▼ Sell$3.1M
KNSA▲ Buy—
KNSA▼ Sell$29K
KNSA▲ Buy—
KNSA▲ Buy—
KNSA▼ Sell$95K
KNSA▲ Buy—
KNSA▲ Buy$111K
KNSA▼ Sell$955K
KNSA▲ Buy$760
KNSA▼ Sell$5K
KNSA▲ Buy—
KNSA▼ Sell$15K
KNSA▲ Buy—
KNSA▲ Buy—
KNSA▼ Sell$10K
KNSA▼ Sell$11K
KNSA▲ Buy—
KNSA▼ Sell$11K
KNSA▲ Buy$112K
KNSA▲ Buy$2K
KNSA▼ Sell$40K
KNSA▼ Sell$1.5M
KNSA▲ Buy—
KNSA▼ Sell$22K
KNSA▲ Buy—
KNSA▼ Sell$53K
KNSA▲ Buy$41K
KNSA▼ Sell$138K
KNSA▼ Sell$209K
KNSA▼ Sell$229K
KNSA▼ Sell$3K
KNSA▲ Buy—
KNSA▼ Sell$13K
KNSA▼ Sell$9K
KNSA▲ Buy—
KNSA▲ Buy$35K
KNSA▼ Sell$410K
KNSA▲ Buy$19K
KNSA▼ Sell$214K
KNSA▼ Sell$230K
KNSA▼ Sell$119K
KNSA▼ Sell$27K
KNSA▲ Buy$53K
KNSA▼ Sell$129K
KNSA▼ Sell$7K
KNSA▲ Buy$744
KNSA▲ Buy—
KNSA▼ Sell$9K
KNSA▲ Buy—
KNSA▼ Sell$13K
KNSA▲ Buy$54K
KNSA▼ Sell$94K
KNSA▼ Sell$311K
KNSA▼ Sell$150K
KNSA▲ Buy—
KNSA▼ Sell$8K
KNSA▲ Buy—
KNSA▼ Sell$12K
KNSA▼ Sell$6K
KNSA▲ Buy—
KNSA▼ Sell$430K
KNSA▲ Buy$53K
KNSA▲ Buy—
KNSA▼ Sell$6K
KNSA▲ Buy—
KNSA▼ Sell$19K
KNSA▲ Buy—
KNSA▼ Sell$6K

We use analytics to understand how market-wall is used. No personal data is sold.